COMPASS 31: A Refined and Abbreviated Composite Autonomic Symptom Score

Sletten, David M.; Suárez, Guillermo A.; Low, Phillip A.; Mandrekar, Jay; Singer, Wolfgang

doi:10.1016/j.mayocp.2012.10.013

Cited by 434 publications

(364 citation statements)

References 11 publications

(8 reference statements)

Supporting

Mentioning

356

Contrasting

Unclassified

Order By: Relevance

“…7 Several studies have suggested the use of questionnaires to evaluate ANSD in order to improve disease management. 2,[7][8][9][10][11] Recently, the questionnaire Composite Autonomic Symptom Score (COMPASS 31) 12 was developed and validated as a self-assessment instrument of autonomic symptoms and function, based on the well-established Autonomic Symptom Profile (ASP). 8 Although not specifically designed for MS, this questionnaire is up-to-date, broadly applicable, easy to administer and based on a scientific approach.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Autonomic Dysfunction in Patients with Multiple Sclerosis

et al. 2015

View full text Add to dashboard Cite

(1):51-55 RESUMOIntrodução: A disfunção do sistema nervoso autónomo é comum na esclerose múltipla e deveria ser explorada na avaliação de rotina. O questionário Composite Autonomic Symptom Score foi validado como instrumento de auto-avaliação de sintomas autonómicos. Objetivos: Determinar a frequência de sintomas autonómicos em doentes com esclerose múltipla através de uma versão portuguesa do Composite Autonomic Symptom Score; comparar os resultados do questionário entre um grupo de doentes e um grupo controlo; avaliar a viabilidade da aplicação deste questionário em doentes portugueses. Material e Métodos: Neste estudo caso-controlo utilizou-se uma tradução portuguesa do questionário para determinar a frequência de sintomas autonómicos em doentes com esclerose múltipla. Resultados: Incluíram-se 103 doentes com esclerose múltipla surto-remissão -idade média 41 anos, mediana de duração da doença 6 anos, EDSS médio 1 -e 80 indivíduos saudáveis. Dos doentes, 97,1% tinham alterações da função autonómica, com significado estatístico nos domínios intolerância ortostática e gastrointestinal. Não encontramos diferenças estatísticas entre doentes (41,7%) sem fatores de confundimento que podiam interferir com a função autonómica (i.e. comorbilidades ou medicações) e o grupo controlo. Discussão: Os resultados obtidos podem estar relacionados com a curta duração de doença, idade jovem e baixo grau de incapacidade dos doentes sem fatores de confundimento. O questionário utilizado não foi desenhado especificamente para a esclerose múltipla e pode não ser tão sensível para sintomas autonómicos mais precoces como para manifestações mais graves da doença. Conclusões: Outros estudos serão necessários para obter resultados mais robustos, validar este questionário e avaliar a sua aplicação nos doentes portugueses. Palavras-chave: Esclerose Múltipla; Portugal; Questionários; Sistema Nervoso Autónomo. ABSTRACT Background:Autonomic nervous system dysfunction is commonly seen in multiple sclerosis patients and should be explored in the routine evaluation. Composite Autonomic Symptom Score questionnaire was validated as a self-assessment instrument of autonomic symptoms. Objectives: Determine the frequency of autonomic symptoms in multiple sclerosis patients through a Portuguese version of Composite Autonomic Symptom Score; compare questionnaire results between patients and a control group; assess the feasibility of this questionnaire application in multiple sclerosis Portuguese patients. Material and Methods:This case-control study used a Portuguese translated version of Composite Autonomic Symptom Score to determine the frequency of autonomic symptoms in multiple sclerosis patients. Results: One-hundred and three relapsing-remitting multiple sclerosis patients -median age 41 years, median disease duration 6 years, median EDSS score 1 -and 80 healthy subjects were included. Alterations in autonomic function were reported in 97.1% of the cases, with statistical significance in orthostatic intolerance and gastrointestinal domain scores....

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence of Autonomic Dysfunction in Patients with Multiple Sclerosis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Accordingly, symptoms of autonomic neuropathy are myriad and include: orthostatic dizziness or fainting, dry eyes or mouth, cold distal extremities, constipation and/or diarrhea, sexual dysfunction, nausea or vomiting especially with meals, urinary incontinence, and changes in sweating. 2 When all or most of these symptoms are present, the diagnosis is fairly clear, but often patients will experience only one or two. In this case, symptoms may easily be mistaken for manifestations of systemic illnesses or medication intolerance, especially in the context of HIV.…”

Section: Introductionmentioning

confidence: 99%

Autonomic Neuropathy in HIV is Unrecognized and Associated with Medical Morbidity

Robinson‐Papp

Sharma

2013

AIDS Patient Care and STDs

View full text Add to dashboard Cite

Autonomic dysfunction is common in HIV. However, its clinical impact is not well understood and its protean symptoms make it difficult to diagnose. We sought to determine: (1) whether autonomic neuropathy is associated with morbidity and predicted mortality in HIV as measured by the Veterans Aging Cohort Study (VACS) index; and (2) if healthcare providers recognize the diagnosis of autonomic neuropathy. Data were obtained from 102 HIVinfected adults enrolled in a prevalence study of autonomic dysfunction from 2011-2012. Participants were predominantly minority with nearly equal numbers of men and women. Most were receiving an antiretroviral regimen with a nucleoside reverse transcriptase inhibitor backbone and a base of a non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or integrase inhibitor. Autonomic neuropathy was defined using a laboratory-based autonomic assessment, the Composite Autonomic Severity Score (CASS). Medical records were reviewed for the year prior to the autonomic assessment. We found that the autonomic neuropathy score (CASS) was associated with the VACS index. We also found that among 53 participants with symptomatic autonomic neuropathy, the diagnosis had been considered for only one. The majority of the symptoms were either unexplained or attributed to medication side effects. This study demonstrates that autonomic neuropathy in HIV is associated with serious co-morbid illnesses known to increase mortality risk, and that HIV healthcare providers rarely consider autonomic neuropathy in their differential diagnoses. Future studies are needed to determine if autonomic neuropathy is an independent risk factor for mortality in HIV, and to raise awareness of its signs and symptoms.

show abstract

“…COMPASS31 comprises 31 questions addressing six domains of autonomic dysfunction (orthostatic symptoms, vasomotor symptoms, secretomotor symptoms, gastrointestinal symptoms, pupillomotor symptoms, and symptoms of bladder dysfunction) [21]. The raw scores of every sub-domain are multiplied by a weighting factor according to its clinical significance, with orthostatic symptoms receiving the highest weighting factor.…”

Section: Autonomic Symptom Questionnaire (Compass31)mentioning

confidence: 99%